Meet Our Alumni
Arrays 4 Cell Nanodevices develops advanced nanotechnology-based solutions to enhance drug delivery systems and improve diagnostic accuracy. Their innovations aim to optimize targeted therapies and streamline the detection of diseases at the molecular level.
Inhibitec aims to revolutionize treatment for patients with psoriasis and Psoriatic Arthritis (PsA) through a novel approach that blocks BAMBI (BMP and Activin Membrane-Bound Inhibitor).
Nanological specializes in nanotechnology-based solutions aimed at enhancing drug delivery and improving therapeutic efficacy. Their innovative approaches focus on developing advanced formulations that optimize treatment outcomes for various medical applications.
STAb Therapeutics develops next-generation immune redirection strategies for solid and hematological tumors. Their innovative T cell redirecting approach combines adoptive cell therapy and bispecific antibodies to enhance T cell engagement and improve anti-tumor responses.
Bioclonal is a novel biotech company dedicated to the in vivo Rational Antibody Discovery . They develop monoclonal antibodies for use in human therapy, which devises an in vivo technology platform of their own creation: RedMabs
MIMO Biosciences offers preclinical research services using custom animal models that mimic genetic alterations in hematological malignancies like multiple myeloma and lymphomas. These models are the result of over a decade of research led by Dr. Jose Angel Martinez-Climent and his team.
Oxolife is a clinical-stage company dedicated to enhancing female fertility through innovative treatments. Their lead product, OXO-001, aims to improve embryo implantation by directly affecting the endometrium and addresses PCOS-related infertility, fulfilling an unmet medical need in the field.
Worldpathol is a biotechnology holding company that drives its developer and manufacturing laboratories through extensive R&D projects focused on recombinant fermentation. Their initiatives aim to create specialized biological products for clients across the pharmaceutical, healthcare, cosmetics, and nutraceutical sectors.
Duponte focuses on developing advanced genetic testing solutions to enhance precision medicine and disease prevention. Their innovative technologies aim to provide deeper insights into genetic profiles, helping to guide personalized healthcare strategies
MiraMoon Pharma is a biotechnology company focused on developing innovative therapies for rare diseases and unmet medical needs. Their approach leverages advanced drug design and delivery technologies to create effective treatments tailored to individual patient profiles.
PlusVitech develops effective and safe therapeutic treatments for Cancer with the purpose of restoring hope to patients who have no other option
Ability Pharmaceuticals is a clinical-stage biopharmaceutical company developing first-in-class therapies to address unmet needs in oncology. Their lead candidate, ABTL0812, is in a Phase 2b trial for metastatic pancreatic cancer and has shown promising results in endometrial and lung cancer.
Ahead Therapeutics is a biotech company that uses a proprietary technology to develop a treatment for different auto-immune disorders. Ahead Therapeutics has developed an innovative solution based on the use of liposomes containing autoantigens.
AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear.
Arjuna Therapeutics is developing a novel class of orally available small molecules to treat aggressive, untreatable cancers. Their lead candidate, Ag5, targets tumors with high Reactive Oxygen Species levels, including KRAS-driven cancers, triple-negative breast cancer, and glioblastoma.
Nostrum Biodiscovery specializes in advanced molecular modeling for drug discovery and enzyme engineering. Their cutting-edge solutions integrate proprietary software, AI, and best-in-class computational tools to accelerate innovation in therapeutics and bio-based chemistry
GAT Biosciences is pioneering the next generation of accessible and non-invasive biopharmaceuticals using sustainable microalgae biofactories. Their innovative approach enables cost-effective and scalable production of therapeutic proteins, advancing a new era in biotechnology.
Nema Health is dedicated to the research and development of innovative personalized immunotherapies for the treatment of cancer in humans and other animal species.
Altum Sequencing offers a precision oncology liquid biopsy and a sequencing platform for molecular cancer monitoring, with clinical validation, commercial traction, and strong IP; applicable across multiple tumor types.
i+Med is the European leader in nanohydrogel-based biomedical devices and controlled-release drug delivery systems, with MDR-certified manufacturing and a unique co-investment model with pharma and medtech partners.
Biohope is a precision diagnostics company (Immunobiogram) that works on personalizing immunosuppressive therapy for transplant patients; CE-marked, commercially active in Europe/LATAM/APAC, with a Mayo Clinic license supporting U.S. entry.
JSN Biomedicals is a Vall d’Hebron Institute of Oncology spin-off developing JSN-101, a first-in-class antibody that reprograms the tumor microenvironment to boost CAR-T and T-cell engager efficacy; raising a €25M Series A.
Oncostellae is a clinical-stage biotech advancing OST-122, a potential best-in-class gut-restricted JAK3/TYK2/ARK5 inhibitor for IBD, with strong Phase 2a safety/efficacy data and a $40M Phase 2b raise underway.
Oncomatryx is a Clinical-stage biotech with a first-in-class FAP-targeting ADC asset modulating the tumor microenvironment, with 100+ patients treated and €158M raised to date; also building a proprietary AI-driven ADC discovery platform.
Oniria Therapeutics is a Vall d’Hebron Institute of Oncology spin-off developing ONR-688, a first-in-class TET2 activator targeting cancer persistence and recurrence, backed by a world-class scientific advisory board.